Background: The relationship between cancer and thrombosis has been studied for years, but reliable guidelines for thromboprophylaxis in that situation are still unclear. Methods: We retrospectively reviewed the files of 3159 consecutive patients with newly diagnosed solid tumors at Jules Bordet Institute from January 2008 to December 2011. Among them, 99 developed a symptomatic thromboembolic episode and were matched with 2 controls (nested case control). The aim was to identify risk factors of thromboembolic events and to validate in our setting the Khorana score. Results: In the cohort study, nodal status ≥ 2, presence of metastases, and primary tumor site were found to be the most significant predictive factors of a thromboembolic event...
Cancer-associated thrombosis (CAT) is a leading cause of death in cancer patients receiving outpati...
Cancer represents a well recognized risk factor for venous thromboembolism. Patients with cancer hav...
The risk of recurrent venous thromboembolism (VTE) in cancer patients despite anticoagulant therapy ...
Magid H AmerDepartment of Medicine, St Rita’s Medical Center, Lima, OH, USABackground: Thrombo...
Even though the Khorana risk score (KRS) has been validated to predict against the development of VT...
Background: Thromboembolic events are important causes of morbidity and mortality in cancer patients...
Background: The awareness of venous thromboembolism (VTE) burden in ambulatory cancer patients is g...
Copyright © 2014 Bohdan Kadlec et al.This is an open access article distributed under the Creative C...
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type ...
Purpose: This study aimed to investigate clinical characteristics of venous thromboembolism (VTE) in...
Cancer patients represent a growing population with drastically difficult care and a lowered quality...
In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients wi...
This thesis describes i) the function of an alternatively spliced coagulation factor in ...
Aim: To evaluate the factors associated with Deep vein thrombosis (DVT) and pulmonary thromboembolis...
Background: Thrombotic events are common in cancer patients and have been associated with an adverse...
Cancer-associated thrombosis (CAT) is a leading cause of death in cancer patients receiving outpati...
Cancer represents a well recognized risk factor for venous thromboembolism. Patients with cancer hav...
The risk of recurrent venous thromboembolism (VTE) in cancer patients despite anticoagulant therapy ...
Magid H AmerDepartment of Medicine, St Rita’s Medical Center, Lima, OH, USABackground: Thrombo...
Even though the Khorana risk score (KRS) has been validated to predict against the development of VT...
Background: Thromboembolic events are important causes of morbidity and mortality in cancer patients...
Background: The awareness of venous thromboembolism (VTE) burden in ambulatory cancer patients is g...
Copyright © 2014 Bohdan Kadlec et al.This is an open access article distributed under the Creative C...
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type ...
Purpose: This study aimed to investigate clinical characteristics of venous thromboembolism (VTE) in...
Cancer patients represent a growing population with drastically difficult care and a lowered quality...
In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients wi...
This thesis describes i) the function of an alternatively spliced coagulation factor in ...
Aim: To evaluate the factors associated with Deep vein thrombosis (DVT) and pulmonary thromboembolis...
Background: Thrombotic events are common in cancer patients and have been associated with an adverse...
Cancer-associated thrombosis (CAT) is a leading cause of death in cancer patients receiving outpati...
Cancer represents a well recognized risk factor for venous thromboembolism. Patients with cancer hav...
The risk of recurrent venous thromboembolism (VTE) in cancer patients despite anticoagulant therapy ...